ALXO Alx Oncology Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALXO

Price (delayed)

$4.87

Market cap

$199M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.03

Enterprise value

$159.57M

ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ...

Highlights
The quick ratio has dropped by 60% year-on-year and by 17% since the previous quarter
ALXO's net income is down by 48% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://alxoncology.com
Peers: OVID

Key stats

What are the main financial stats of ALXO
Market
Shares outstanding
40.86M
Market cap
$199M
Enterprise value
$159.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$123.42M
EBITDA
-$123.08M
Free cash flow
-$90.65M
Per share
EPS
-$3.03
Free cash flow per share
-$2.23
Book value per share
$6.46
Revenue per share
$0
TBVPS
$7.53
Balance sheet
Total assets
$306.49M
Total liabilities
$43.03M
Debt
$9.39M
Equity
$263.46M
Working capital
$242.64M
Liquidity
Debt to equity
0.04
Current ratio
9.57
Quick ratio
9.4
Net debt/EBITDA
0.32
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-37%
Return on equity
-40.8%
Return on invested capital
-53.2%
Return on capital employed
-44.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALXO stock price

How has the Alx Oncology Holdings stock price performed over time
Intraday
1.46%
1 week
-2.6%
1 month
-30.13%
1 year
-73.73%
YTD
-56.79%
QTD
-56.79%

Financial performance

How have Alx Oncology Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$127.44M
Net income
-$123.48M
Gross margin
N/A
Net margin
N/A
ALXO's operating income has shrunk by 53% YoY and by 3% QoQ
ALXO's net income is down by 48% year-on-year

Growth

What is Alx Oncology Holdings's growth rate over time

Valuation

What is Alx Oncology Holdings stock price valuation
P/E
N/A
P/B
0.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 46% year-on-year
The price to book (P/B) is 51% less than the last 4 quarters average of 1.5
Alx Oncology Holdings's equity has decreased by 27% YoY and by 8% QoQ

Efficiency

How efficient is Alx Oncology Holdings business performance
ALXO's return on equity has dropped by 92% year-on-year and by 10% since the previous quarter
The return on assets has dropped by 81% year-on-year and by 8% since the previous quarter
ALXO's return on invested capital is up by 24% since the previous quarter

Dividends

What is ALXO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALXO.

Financial health

How did Alx Oncology Holdings financials performed over time
The total liabilities has surged by 151% year-on-year and by 40% since the previous quarter
Alx Oncology Holdings's current ratio has plunged by 60% YoY and by 17% from the previous quarter
The debt is 96% smaller than the equity
Alx Oncology Holdings's equity has decreased by 27% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.